## PAPER

Check for updates

# Analytical determination of heroin, fentanyl and fentalogues using high-performance liquid chromatography with diode array and amperometric detection†

Hadil M. Elbardisy, [iD] [ab] Christopher W. Foster, [iD] [a] Loanda Cumba,[c] Lysbeth H. Antonides,[a] Nicolas Gilbert,[ad] Christopher J. Schofield,[de] Tarek S. Belal, [iD] [f] Wael Talaat,[b] Oliver B. Sutcliffe, [iD] [ad] Hoda G. Daabees[g] and Craig E. Banks [iD] *[a]

Over recent years there has been a progressive increase in the adulteration of common illicit street drugs, such as heroin and cocaine, with fentanyl and its derivatives (fentalogues) being the cause of over doses ending with fatal repercussions. Consequently, there is a need for the development of sensitive, selective and reliable analytical protocols for their separation and quantification. Herein, we report for the first time, a combination of high-performance liquid chromatography with a dual-diode array and electrochemical (amperometric) detector achieved for the simultaneous detection and quantification of heroin (HRN), fentanyl and ten fentalogues; the amperometric detection is achieved using a commercially available impinging jet flow-cell that incorporates *in-house* screen-printed graphite macroelectrodes (SPEs). Both protocols are analytically compared and contrasted in terms of their experimental parameters and chromatographic conditions with the separation and quantification being optimized, with these protocols demonstrating a high sensitivity and reproducibility. The proposed methods were successfully applied for the analysis of the investigated drugs of abuse, in the presence of common adulterants (*e.g.* caffeine, paracetamol and benzocaine), co-formulated excipients (starch, lactose, aerosil 200, *etc.*) and simultaneously within seized street samples.

## Introduction

Fentanyl (Scheme 1), (*N*-phenyl-*N*-[1-(2-phenylethyl)piperidin-4-yl]propanamide, **2c**) is a synthetic narcotic analgesic, a potent μ-opioid receptor agonist that is one hundred times more potent than heroin (HRN) (Scheme 1).[1,2] Fentanyl was

[a]*Faculty of Science and Engineering, Manchester Metropolitan University, Chester Street, Manchester, M1 5GD, UK. E-mail: c.banks@mmu.ac.uk; Web: http://www.craigbanksresearch.com; Fax: +44 (0)1612476831; Tel: +44 (0)1612471196*

[b]*Pharmaceutical Analysis Department, Faculty of Pharmacy, Damanhour University, Damanhour, 22511, Egypt*

[c]*Faculty of Science & Health, Dublin City University, Glasnevin, Whitehall, Dublin 9, Ireland*

[d]*MANchester DRug Analysis and Knowledge Exchange (MANDRAKE), Faculty of Science and Engineering, Manchester Metropolitan University, Chester Street, Manchester, M1 5GD, UK*

[e]*Greater Manchester Police, Openshaw Complex, Lawton Street, Openshaw, Manchester, M11 2NS, UK*

[f]*Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt*

[g]*Pharmaceutical Chemistry Department, Faculty of Pharmacy, Damanhour University, Damanhour, 22511, Egypt*

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ay00009g

primarily introduced by Janssen Pharmaceutica in the early 1960's as an intravenous anesthetic during surgical operations.[1] In the late 1980's, the same pharmaceutical company developed transdermal fentanyl patches under the trade name Duragesic® to relieve pain in cancer patients.[3] It was not until the 1970's when the illicit use of "China Girl" or "China White" (alias given to fentanyl and its analogues) started to appear in California where it began to be substituted for HRN leading to unprecedented mortality rates.[4] Over recent decades, adulteration of common illicit street drugs with fentanyl (owing to its low production cost, high potency and induced-euphoric properties) has made it a favorable "*high*" in the recreational drug market.[5]

According to the U.S. Federal Control Substances Act 2017 published by the U.S. Department of Justice, fentanyl is classified as a Schedule II narcotic, since 1970. Recently, the Drug Enforcement Administration (DEA) in the U.S. provisionally listed structurally related fentanyl substances such as acetylfentanyl (**2b**) and butyrfentanyl (**2f**) under Schedule I of the Controlled Substances Act.[6] Worldwide the fentanyl crisis has proliferated at an unprecedented rate posing significant public health challenges. In the U.S., 1013 fentanyl-related deaths were reported over the period 2005–2007, which were attributed to fentanyl/HRN mixtures. In March 2017, China controlled four

R = 
‡CH₂OMe  (**2a**, methoxyacetylfentanyl.HCl)   ‡CH₃  (**2b**, acetylfentanyl.HCl)

‡CH₂CH₃  (**2c**, fentanyl.HCl)   ‡◁  (**2d**, cyclopropylfentanyl.HCl)

‡CH(CH₃)₂  (**2e**, isobutyrfentanyl.HCl)   ‡(CH₂)₂CH₃  (**2f**, butyrfentanyl.HCl)

‡◻  (**2g**, cyclobutylfentanyl.HCl)   ‡Ph  (**2h**, benzoylfentanyl.HCl)

‡CH₂CH(CH₃)₂  (**2i**, isovalerylfentanyl.HCl)   ‡(CH₂)₃CH₃  (**2j**, valerylfentanyl.HCl)

‡⬠  (**2k**, cyclopentylfentanyl.HCl)

(HRN, heroin)    (COC, cocaine)

**Scheme 1** Chemical synthesis and structures of fentanyl (**2c**), fentalogues (**2a**, **2b**, **2d–2k**), heroin (HRN) and cocaine (COC).

types of fentanyl analogues under the Chinese law, after a meeting held between the U.S. In Europe, according to a commentary published in the International Journal of Drug Policy,[7] Sweden was the first country to report 8 fentanyl-related deaths in 1994. However, Estonia recorded the highest fentanyl mortality rates in the EU, with an estimate of 1100 deaths over the period 2005–2013; deaths peaked in 2012 and reached 170, which was 11 times higher than the European average.[7]

Due to the high potency and dangerous impact of fentanyl and its analogues worldwide, their quantitative determination is of considerable importance. Within the literature, fentanyl is mainly determined *via* two major techniques, either chromatography (with the appropriate detector) or electrochemistry; Table 1 provides a thorough overview of these methodologies applied to the detection of fentanyl and its fentalogues. Chromatography and related techniques have extensively been reported but are generally considered expensive and require expert users for their efficient operation. In the case of electrochemical methodologies, these are more limited and are yet be utilized for the separation of HRN, fentanyl and fentalogues. Of note, from the inspection of Table 1, only one hybrid technique high-performance liquid chromatography-photolysis-electrochemical detection[8] has been utilized towards fentanyl detection, however, only used for the analysis of **2c**.

Herein, we develop for the first time, a combination of high-performance liquid chromatography-diode array detection (HPLC-DAD) and high-performance liquid chromatography-amperometric detection (HPLC-AD) methods for the

separation and quantification of fentanyl (**2c**), ten fentalogues (**2a**, **2b**, **2d–2k**) and HRN. This approach uses screen-printed graphite macroelectrodes (SPEs), as they are an advantageous electrochemical sensing platform that can be utilized in various quantification methods, owing to their economy of scales, simplicity and reproducibility.[9–12]

## Results and discussion

### Electrochemical measurement of the target analytes using cyclic voltammetry

Fig. 1 depicts the individual voltammetric profiles for fentanyl (**2c**), HRN and COC utilizing SPEs. In consideration of previous literature, fentanyl (**2c**)[8,13] and cocaine (COC) (Scheme 1),[14,15] as observed within Fig. 1, likely undergo an irreversible electrochemical oxidation/process as a result of the tertiary amine but in fact is likely more complex with the oxidation peak containing a contribution from more complex processes with formation of hydroxylated compounds and oxidation to give quinone imine groups. Since this is the first electrochemical report of the electrochemical oxidation of fentanyl, the exact mechanism needs further elucidation. Similarly, the observed electrochemical signature for heroin (HRN) is likely due to the irreversible electrochemical oxidation of the tertiary amine corresponding to the formation of a secondary amine.[16,17] Fig. S1† displays typical cyclic voltammograms for each of HRN, COC, fentanyl and fentalogues, at pH 2.0, 7.0 and 10.0, utilizing SPEs. It is apparent that at pH 2.0 there are no apparent

Table 1 Comparison of prior methods, chromatographically and electrochemically for analysis of the range of drugs studied within this paper

| Analytical method | Target analytes | Total run time (min) | Limit of detection (LOD)[b] | Limit of quantitation (LOQ)[c] | Linearity range | Ref. |
|---|---|---|---|---|---|---|
| SPE-GC/MS[a] | HRN and (2c) | 17 | $0.4 \times 10^{-3}$ to $4.62 \times 10^{-3}$ µg mL⁻¹ | $1.3 \times 10^{-3}$ to $14 \times 10^{-3}$ µg mL⁻¹ | $20 \times 10^{-3}$ to $1500 \times 10^{-3}$ µg mL⁻¹ | 26 |
| UPLC-MS/MS | HRN and (2c) | 8 | 0.03–0.21 pg injected | 0.1–0.7 pg injected | 0.1–1000 pg injected | 27 |
| TD-DART-MS and IMS | HRN, (2b), (2c), (2e), (2h), (2j) and (2k) | Δ[d] | $8.807 \times 10^{-2}$ to 2.55 ng[e] | Δ | 0.5–20 ng per wipe (TD-DART-MS) 1.0–100 ng per wipe (IMS) | 28 |
| LC-MS/MS | HRN and (2c) | 20 | $8.0 \times 10^{-5}$ to $2.0 \times 10^{-3}$ µg mL⁻¹ | $1.0 \times 10^{-4}$ µg mL⁻¹ | $1.0 \times 10^{-4}$ to $7.60 \times 10^{-1}$ µg mL⁻¹ | 29 |
| LC-MS/MS | (2b), (2c), (2e), (2f), and (2j) | 13.5 | $0.017 \times 10^{-3}$ to $0.056 \times 10^{-3}$ mg mL⁻¹ | $0.10 \times 10^{-3}$ to $0.50 \times 10^{-3}$ µg mL⁻¹ | $0.1 \times 10^{-3}$ to $50 \times 10^{-3}$ µg mL⁻¹ | 30 |
| LC-MS/MS | (2b) and (2c) | 5 | Δ | $0.1 \times 10^{-3}$ to $1.0 \times 10^{-3}$ µg mL⁻¹ | $0.10 \times 10^{-3}$ to $40 \times 10^{-3}$ µg mL⁻¹ | 31 |
| LC-MS | (2c) | Δ | $0.2 \times 10^{-3}$ to $0.6 \times 10^{-3}$ µg mL⁻¹ | $0.6 \times 10^{-3}$ to $2 \times 10^{-3}$ µg mL⁻¹ | Δ | 32 |
| GC/MS | (2c) | 23 | $0.08 \times 10^{-3}$ µg mL⁻¹ | $0.5 \times 10^{-3}$ µg mL⁻¹ | $0.5 \times 10^{-3}$ to $50 \times 10^{-3}$ µg mL⁻¹ | 33 |
| HPLC utilizing absorbance rationing | (2c) | 20 | Qualitative analysis | Qualitative analysis | Qualitative analysis | 34 |
| Potentiometric method using PVC membrane electrode | (2c) | — | 1.83 µg mL⁻¹ | Δ | $3.36$–$3.36 \times 10^{3}$ µg mL⁻¹ | 35 |
| Potentiometric method using plastic membrane electrode (PVC) | (2c) | — | 2.11 µg mL⁻¹ | Δ | $3.36$–$3.36 \times 10^{3}$ µg mL⁻¹ | 36 |
| Electrochemiluminescence, cyclic voltammetry using GC electrode | (2c) | — | $2.86 \times 10^{-3}$ µg mL⁻¹ | Δ | $3.36 \times 10^{-3}$ to 33.6 µg mL⁻¹ | 37 |
| ASV using SDME | (2c) | — | $1.68 \times 10^{-2}$ µg mL⁻¹ | Δ | $3.36 \times 10^{-2}$ to $3.36 \times 10^{-1}$ µg mL⁻¹ | 38 |
| Polarography | (2c) | — | $1.68 \times 10^{-1}$ µg mL⁻¹ | Δ | $3.36 \times 10^{-1}$ to 6.73 µg mL⁻¹ | 39 |
| HPLC-UV-EC | (2c) | | Δ | Δ | Δ | 8 |
| This work, HPLC-DAD (Method I) | HRN, (2a)–(2k) | 30 | HRN: $16.2 \times 10^{-2}$ µg mL⁻¹; 2a: $22.49 \times 10^{-2}$ µg mL⁻¹; 2b: $24.47 \times 10^{-2}$ µg mL⁻¹; 2c: $41.67 \times 10^{-2}$ µg mL⁻¹; 2d: $49.67 \times 10^{-2}$ µg mL⁻¹; 2e: $68.80 \times 10^{-2}$ µg mL⁻¹; 2f: $74.63 \times 10^{-2}$ µg mL⁻¹; 2g: $95.54 \times 10^{-2}$ µg mL⁻¹; 2h: $96.77 \times 10^{-2}$ µg mL⁻¹; 2i: 1.15 µg mL⁻¹; 2j: 1.13 µg mL⁻¹; 2k: 1.36 µg mL⁻¹ | HRN: $54 \times 10^{-2}$ µg mL⁻¹; 2a: $74.96 \times 10^{-2}$ µg mL⁻¹; 2b: $81.57 \times 10^{-2}$ µg mL⁻¹; 2c: 1.39 µg mL⁻¹; 2d: 1.66 µg mL⁻¹; 2e: 2.29 µg mL⁻¹; 2f: 2.49 µg mL⁻¹; 2g: 3.18 µg mL⁻¹; 2h: 3.23 µg mL⁻¹; 2i: 3.85 µg mL⁻¹; 2j: 4.5 µg mL⁻¹; 2k: 4.55 µg mL⁻¹ | 5.0–120 µg mL⁻¹ | — |
| This work, HPLC-AD (Method II) | | 30 | HRN: 0.45 µg mL⁻¹; 2a: 0.48 µg mL⁻¹; 2b: 0.48 µg mL⁻¹; 2c: 0.77 µg mL⁻¹; 2d: 0.91 µg mL⁻¹; 2e: 1.19 µg mL⁻¹; 2f: 1.28 µg mL⁻¹; 2g: 1.71 µg mL⁻¹ | HRN: 1.49 µg mL⁻¹; 2a: 1.61 µg mL⁻¹; 2b: 1.61 µg mL⁻¹; 2c: 2.58 µg mL⁻¹; 2d: 3.04 µg mL⁻¹; 2e: 3.95 µg mL⁻¹; 2f: 4.27 µg mL⁻¹; 2g: 5.71 µg mL⁻¹ | 10.0–120 µg mL⁻¹ | — |

Table 1 (Contd.)

| Analytical method | Target analytes | Total run time (min) | Limit of detection (LOD)[b] | Limit of quantitation (LOQ)[c] | Linearity range | Ref. |
|---|---|---|---|---|---|---|
| | | | 2h: 1.68 µg mL$^{-1}$ | 2h: 5.59 µg mL$^{-1}$ | | |
| | | | 2i: 2.60 µg mL$^{-1}$ | 2i: 8.68 µg mL$^{-1}$ | | |
| | | | 2j: 2.78 µg mL$^{-1}$ | 2j: 9.26 µg mL$^{-1}$ | | |
| | | | 2k: 2.93 µg mL$^{-1}$ | 2k: 9.76 µg mL$^{-1}$ | | |

[a] SPE-GC/MS: solid phase extraction-gas chromatography/mass spectrometry; UPLC-MS/MS: ultra-performance liquid chromatography tandem mass spectrometry; TD-DART-MS: thermal desorption-direct analysis in real time-mass spectrometry; IMS: ion mobility spectrometry; LC-MS/MS: liquid chromatography-tandem mass spectrometry; LC-MS: liquid chromatography-mass spectrometry; GC/MS: gas chromatography-mass spectrometry; PVC: polyvinyl chloride; GC: glassy carbon electrode; ASV: adsorptive stripping voltammetry; SDME: static dropping mercury electrode; HPLC-UV-EC: high-performance liquid chromatography-photolysis-electrochemical detection. [b] LOD is a range of the smallest and biggest LOD for the quantified analytes. [c] LOQ is a range of the smallest and biggest LOQ for the quantified analytes. [d] Δ = not disclosed. [e] LOD$_{90}$ = corresponds to the lowest mass which can be detected of a wipe with a 90% probability of true detection.



Fig. 1 Typical cyclic voltammograms obtained separately for (2c), HRN and COC; solution composition: 50 µg mL$^{-1}$ of each drug within a 0.04 M B–R buffer pH 7.0; scan rate: 50 mV s$^{-1}$.

electrochemical oxidation waves/signal of the target analytes (Fig. S1A†) within the accessible electrochemical window. Additionally Fig. S1B and S1C† overview the response of the HRN, COC, fentanyl and fentalogues in pH 10 and 7; Table S1† compares the peak potentials of all the drug analytes at the pH's 2, 7 and 10. Note that analytically useful voltammetric peaks are obtained for all the analytes in pH 7.0; consequently, pH 7.0 was chosen as the optimum pH for the voltammetric analysis of the target analytes/drugs. In summary, it is clear that in consideration of the peak potentials of all the studied drugs/analytes, they all overlap, in terms of electrochemical oxidation potentials, so if they were all present in a real sample, such as in the case of a street sample with an unknown composition, as is typically the case, all analytes present within the sample cannot be unambiguously determined. Due to the inability of a direct electroanalytical approach to separate and quantify HRN, (2c) and fentalogues (2a, 2b, 2d–2k), attention was turned to the use of chromatography to separate and analyze the drugs of interest, using high-performance liquid chromatography with DAD and AD detection.

### Optimization of the chromatographic conditions

**Configuration and arrangement of HPLC-DAD and HPLC-AD protocol.** Following Zuway et al., the best arrangement of the detectors is by placing the DAD preceding the AD and connecting them via PTFE tubing (230 × 1.6 mm, i.d. 0.3 mm, internal volume: 16.25 µL), as this configuration reduces the system back-pressure thus minimizing leakages from the flow-cell occurring when the detectors arrangement is switched.[9] Also, Zuway et al., reported using two types of flow-cells for amperometric analysis of synthetic cathinones namely a commercially available impinging jet flow-cell and custom-made iCell channel flow-cell, however, in the present work only the impinging jet flow-cell was used, as Zuway et al., demonstrated that iCell flow-cell is not as sensitive due to the large internal chamber volume accommodating the SPE,

increasing the sample dispersion, diluting the analytes, therefore reducing the SPEs sensor sensitivity *via* mass transfer/diffusion to the electrode surface.[9,18–20]

**Stationary phase.** Different column types (packing material) were explored for the simultaneous and efficient separation of HRN, fentanyl and its fentalogues, in order to achieve optimal separation, good resolution ($R_s$) between peaks, reasonable retention and run time and to obtain sharp symmetric peaks. The tested columns were: Phenomenex, Hyperclone C18 (150 × 4.6 mm, i.d. 5 μm), Hypurity™ Elite hypersil C18 (100 × 3 mm, i.d. 3 μm), Greysil C8 (100 × 3.2 mm, i.d. 5 μm), ACE 5 C18-AR (150 × 4.6 mm, i.d. 5 μm) and Eclipse XDB-C8 (150 × 4.6 mm, i.d. 5 μm). The first column retained the drugs for a significantly long time and requires the acetonitrile ratio to increase to 40% to have a reasonable run time, however this will affect the electrochemical detection, which favors a low ratio of organic present. The second and third columns eluted with the drugs overlapping together within just 15 minutes; decreasing the ratio of acetonitrile to 20% resulted in the elution of all drugs as very broad peaks. The fourth column eluted the drugs within a reasonable run time as sharp symmetric peaks, however, isovaleryl- and valerylfentanyl (**2i** and **2j** respectively) overlapped together and eluted as one broad peak. The fifth column,

Eclipse XDB-C8 (150 × 4.6 mm, i.d. 5 μm), fulfilled all the chromatographic requirements and was chosen for this study.

**Mobile phase.** Previous papers for the chromatographic determination of fentanyl, reports the use of formic acid or ammonium formate as the aqueous phase with acetonitrile as the organic modifier.[6–8] Therefore, an isocratic mobile phase of ammonium formate and acetonitrile was favored over gradient elution programs despite of their advantages of shortening the analysis time and optimizing the separation. This was explained by Zuway *et al.*, who adapted an isocratic method for HPLC-AD, to prevent the fluctuation of electrolyte composition during electrochemical detection, and used reduced ratio of organic modifier (10 mM ammonium acetate : methanol 70 : 30% v/v) in combination with a suitable electrolyte (100 mM KCl).[1] Similarly, we used a mobile phase consists of 20 mM ammonium formate : acetonitrile 70 : 30% v/v and added 100 mM KCl to the aqueous phase as an electrolyte. Attempts to decrease the organic modifier percentage were unfavorable as it affected the peaks symmetry and prolonged the run time over 30 minutes.

**Ionic strength of ammonium formate buffer.** The effect of the ionic strength of the chosen buffer was studied using 5, 10, 20, 30, 40, 50 mM ammonium formate. In HPLC-AD, it was found that increasing the molarity of the buffer increases the baseline noise, however, the total run time decreases and using



**Fig. 2** (A) Representative HPLC-DAD chromatograms for a solution containing 50 μg mL$^{-1}$ of each of HRN, fentanyl (**2c**) and fentalogues (**2a**, **2b**, **2d–2k**) using an Eclipse XDB-C8 column (150 × 4.6 mm, i.d. 5 μm); mobile phase: acetonitrile : 20 mM ammonium formate–100 mM potassium chloride buffer (pH 7.0) (30 : 70% v/v); flow rate 1.5 mL min$^{-1}$, detector wavelength (UV): 205 nm and column temperature: 25 °C. (B) Representative amperogram for a solution containing 50 μg mL$^{-1}$ of each of HRN, fentanyl and its 10 derivatives obtained using HPLC-AD flow cell system. (C) HPLC-DAD chromatogram for a solution containing 50 μg mL$^{-1}$ of each of COC, fentanyl and its 10 derivatives. (D) Representative amperogram for a solution containing 50 μg mL$^{-1}$ of each of COC, fentanyl and its 10 derivatives obtained using HPLC-AD flow cell system.

**Table 2** Summary of HPLC-DAD data for the quantification of HRN, fentanyl (**2c**) and fentalogues (**2a**, **2b**, **2d**–**2k**) obtained using Eclipse XDB-C8 column (150 × 4.6 mm, i.d. 5 µm); mobile phase [acetonitrile : 20 mM ammonium formate–100 mM potassium chloride buffer (pH 7.0) (30 : 70% v/v)]; flow rate = 1.5 mL min⁻¹; detector wavelength (UV) = 205 nm; and column temperature = 25 °C

| Parameters | Analyte | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | HRN | (**2a**) | (**2b**) | (**2c**) | (**2d**) | (**2e**) | (**2f**) | (**2g**) | (**2h**) | (**2i**) | (**2j**) | (**2k**) |
| $R^{2a}$ | $0.999^b$ | $0.999^c$ | $0.999^d$ | $0.999^e$ | $0.999^f$ | $0.999^g$ | $0.999^h$ | $0.999^i$ | $0.999^j$ | $0.999^k$ | $0.999^l$ | $0.999^m$ |
| $\text{LOD}^n$ (µg mL⁻¹) | $16.20 \times 10^{-2}$ | $22.49 \times 10^{-2}$ | $24.47 \times 10^{-2}$ | $41.67 \times 10^{-2}$ | $49.67 \times 10^{-2}$ | $68.80 \times 10^{-2}$ | $74.63 \times 10^{-2}$ | $95.54 \times 10^{-2}$ | $96.77 \times 10^{-2}$ | 1.15 | 1.35 | 1.36 |
| $\text{LOQ}^o$ (µg mL⁻¹) | $54.0 \times 10^{-2}$ | $74.96 \times 10^{-2}$ | $81.57 \times 10^{-2}$ | 1.39 | 1.66 | 2.29 | 2.49 | 3.18 | 3.23 | 3.85 | 4.50 | 4.55 |
| **Precision (% RSD, $n = 6$)** | | | | | | | | | | | | |
| 5 µg mL⁻¹ | 0.29 | 0.21 | 0.78 | 0.39 | 0.40 | 0.43 | 0.74 | 0.56 | 0.28 | 0.34 | 1.0 | 0.91 |
| 10 µg mL⁻¹ | 0.42 | 0.42 | 0.94 | 0.86 | 0.64 | 0.42 | 1.0 | 1.0 | 0.75 | 0.53 | 0.55 | 0.53 |
| 40 µg mL⁻¹ | 0.42 | 0.54 | 0.75 | 1.0 | 0.64 | 0.38 | 0.62 | 0.10 | 0.54 | 0.59 | 0.99 | 1.0 |
| 80 µg mL⁻¹ | 0.90 | 0.77 | 0.66 | 0.55 | 0.61 | 0.83 | 0.74 | 0.55 | 0.58 | 0.55 | 0.46 | 0.46 |
| 120 µg mL⁻¹ | 0.96 | 0.73 | 0.98 | 0.59 | 0.81 | 0.79 | 0.67 | 0.99 | 0.92 | 0.88 | 0.95 | 0.82 |
| **System suitability parameters** | | | | | | | | | | | | |
| $t_R \pm \text{SD (min)}^p$ ($n = 6$) | 2.79 ± 0.03 | 4.09 ± 0.04 | 4.79 ± 0.02 | 8.10 ± 0.04 | 10.79 ± 0.08 | 13.20 ± 0.05 | 14.26 ± 0.07 | 18.08 ± 0.01 | 20.65 ± 0.05 | 25.50 ± 0.03 | 27.64 ± 0.04 | 29.42 ± 0.06 |
| $\text{RRT}^q$ | 0.34 | 0.50 | 0.59 | 1.0 | 1.33 | 1.63 | 1.76 | 2.23 | 2.55 | 3.15 | 3.41 | 3.63 |
| $k'^r$ | 2.10 | 3.54 | 4.32 | 8.0 | 10.99 | 13.67 | 14.84 | 19.09 | 21.94 | 27.33 | 29.71 | 31.69 |
| $N \text{ (plates)}^s$ | 2111 | 5165 | 6624 | 8396 | 8930 | 9238 | 9610 | 9563 | 9560 | 9853 | 10 223 | 10 196 |
| $\text{HETP (m)}^t$ | $7.11 \times 10^{-5}$ | $2.90 \times 10^{-5}$ | $2.26 \times 10^{-5}$ | $1.79 \times 10^{-5}$ | $1.68 \times 10^{-5}$ | $1.62 \times 10^{-5}$ | $1.56 \times 10^{-5}$ | $1.57 \times 10^{-5}$ | $1.57 \times 10^{-5}$ | $1.52 \times 10^{-5}$ | $1.47 \times 10^{-5}$ | $1.47 \times 10^{-5}$ |
| $R_s^u$ | — | 4.69 | 2.82 | 10.41 | 6.57 | 4.75 | 1.88 | 5.74 | 3.23 | 5.13 | 2.00 | 1.59 |
| $A_s^v$ | 1.29 | 1.43 | 1.33 | 1.00 | 0.92 | 0.91 | 0.88 | 0.82 | 0.88 | 0.80 | 0.93 | 0.84 |
| $\alpha^w$ | — | 1.69 | 1.22 | 1.85 | 1.37 | 1.24 | 1.09 | 1.29 | 1.15 | 1.25 | 1.09 | 1.07 |

$^a$ $R^2$: co-efficient of regression. $^b$ $y = 25.543x - 21.487$. $^c$ $y = 21.14x - 7.931$. $^d$ $y = 22.659x - 23.03$. $^e$ $y = 21.87x - 25.32$. $^f$ $y = 23.737x - 31.553$. $^g$ $y = 21.89x - 40.11$. $^h$ $y = 22.15x - 61.48$. $^i$ $y = 20.74x - 44.90$. $^j$ $y = 20.74x - 44.90$. $^k$ $y = 18.94x - 40.41$. $^l$ $y = 18.70x - 43.54$. $^m$ $y = 18.51x - 44.17$. $^n$ LOD: limit of detection. $^o$ LOQ: limit of quantitation. $^p$ $t_R$: retention time in minutes for drugs eluted from the chromatographic column (Method I). $^q$ RRT: relative retention time (determined with respect to (**2c**) retention time obtained from Method I). $^r$ $k'$: capacity factor. $^s$ $N$: number of theoretical plates expressed in plates per m. $^t$ HETP: height equivalent to theoretical plate expressed in m. $^u$ $R_s$: resolution between two successive eluted peaks. $^v$ $A_s$: asymmetry factor. $^w$ $\alpha$: relative retention factor.

a very low molarity resulted in fronted peaks. In the case of HPLC-AD, changing the buffer molarity did not affect the amperograms or the amperometric response (peak current, µA). Therefore, 20 mM ammonium formate was chosen since it gives the best compromise in terms of peak shape and symmetry and total run time (30 minutes).

**pH of the aqueous phase.** After selection of the best buffer and optimising its molarity, the effect of pH of the aqueous phase (20 mM ammonium formate + 100 mM KCl) was studied over the range 3.0–8.0 (at 1 pH unit increments). In case of HPLC-DAD, it was found that using low pHs (*i.e.* pH 3.0, 4.0 and 5.0) resulted in a noisy baseline, asymmetric peaks, short run time, HRN and methoxyacetylfentanyl (**2a**) peaks overlap together and cybutylfentanyl (**2g**) and benzoylfentanyl (**2h**) eluted as one broad peak. Observing HPLC-DAD chromatograms at pH 7.0 and 8.0, it was found that pH 7.0 gave the best peak symmetry with all peaks being resolved with a total run time of 30 minutes, however, using pH 8.0 prolonged the run time (last peak eluted at 74 minutes) and the baseline became noisy. In HPLC-AD, cybutylfentanyl (**2g**) and benzoylfentanyl (**2h**) are overlapped the same way in HPLC-DAD, by increasing

the pH above 3.0 they begin to separate, and they are completely resolved at pH 6.0. The electrochemical oxidation of HRN at pH's 3.0 and 4.0 (within the HPLC-AD flow cell system) does not give rise to any sufficient detection, however at pH 5.0 a miniaturized peak appears but upon changing the pH to 8.0 the amperometric signal increases to its maximum. Nonetheless, all the fentalogues recorded the highest current intensity at pH 7.0. It also important to note, that the prolonged run time at pH 8.0, eluded us from using it. Therefore, pH 7.0 was the optimum pH for this study.

**Detection wavelength.** In order to quantify HRN, fentanyl and its derivatives accurately and maximize the HPLC-DAD sensitivity; the photo diode array detector (DAD) was set at 205 nm ($\lambda_{max}$ for HRN, fentanyl, and it's fentalogues) (Fig. S2A and S2B†), which coincides with the literature that used the same wavelength for fentanyl[9] and HRN[10] quantification.

**Linear velocity of mobile phase.** Linear velocity of the mobile phase is an important factor to be studied as it affects peak symmetry, resolution ($R_s$) between closely eluted peaks and total run time. The studied flow rates were: 1.1, 1.3, 1.5, 1.7 mL min⁻¹. In HPLC-DAD, symmetry of the peaks was found to

be good in all of the studied flow rates and the difference between the total run-time in the four flow rates was not significantly big. Therefore, resolution ($R_s$) between the closest two peaks in the chromatogram was the key factor in choosing the flow rate. The closest two eluted peaks are the last two peaks in the chromatogram (valerylfentanyl (**2j**) and cyclopentylfentanyl (**2k**)), flow rate = 1.7 mL min$^{-1}$ gave the shortest run time but the resolution ($R_s$) between valerylfentanyl (**2j**) and cyclopentylfentanyl (**2k**) dropped to 1.49. Therefore, flow rate 1.5 mL min$^{-1}$ was chosen to not prolong the run time (total run time = 30 minutes) and the resolution ($R_s$) between the last two eluting peaks was acceptable ($R_s$ = 1.54). In HPLC-AD, the mobile phase flow rate did not have any significant effect on the analytes' amperometric response (peak current, μA), *i.e.* peak heights (current intensity, μA) of all drugs remained unchanged by changing the flow rate (Fig. S3A†).

**Optimization of the electrochemical potential for HPLC-AD.** In order to increase the sensitivity of amperometric measurements and obtain optimum detector response, the potential has to be optimized. From the recent data we obtained from cyclic voltammetry (CV) it was apparent that each of HRN, fentanyl and its derivatives has an anodic peak at $E_p \approx$ +0.9 V, thus the amperometric response (peak current, μA) was measured as a function of the anodic potential (V) over the range ($E$ = +0.8 to +1.2 V). Using potential of +0.8 V resulted in a poor signal for all analytes that increased gradually until reaching a maximum value at potential of +1.0 V (Fig. S3B†).

Following the optimization of all the experimental/chromatographic conditions, typical HPLC-DAD chromatograms and HPLC-AD amperograms for HRN and fentalogues are presented in Fig. 2A and B, respectively. Fig. 2C and D represent HPLC-DAD chromatograms and HPLC-AD amperograms for COC, (**2c**) and fentalogues (**2a**, **2b**, **2d–2k**). It should be noted that HRN and COC elute at very similar retention times ($t_R$) (COC; $t_R$ in HPLC-DAD = 2.65 min), therefore, analysis of HRN and COC in the same sample is likely not feasible. The proposed analytical methodologies were validated according to the ICH recommendations;[21] all validation parameters are presented in Tables 2, 3, S2 and S3.†

Analytical performance was next considered *via* calibration curves for the HPLC-DAD and HPLC-AD methods. The LOD's (3-sigma) are found to range from 0.16–1.36 μg mL$^{-1}$ and 0.45–2.93 μg mL$^{-1}$, for HPLC-DAD and HPLC-AD, respectively (Tables 2 and 3). The LOQ's (10-sigma) range from 0.54–4.55 μg mL$^{-1}$ and 1.49–9.76 μg mL$^{-1}$, for HPLC-DAD and HPLC-AD, respectively (Tables 2 and 3). However, through comparing the LOD and LOQ of both analytical approaches we can conclude that HPLC-DAD is relatively more analytically sensitive than that of the HPLC-AD. All system suitability parameters are listed in Tables 2 and 3. The selectivity of both methods was investigated by injecting potential adulterants commonly found in street samples, which are: caffeine (Cf), paracetamol (Pc) and benzocaine (Bz). Unfortunately, the chromatographic approach could not separate (Cf) from (Pc), as the two peaks elute at similar retention times. Consequently, two adulterated solutions were

**Table 3** Summary of HPLC-AD validation data for the quantification of HRN, fentanyl (**2c**) and fentalogues (**2a**, **2b**, **2d–2k**) obtained utilizing HPLC-AD. The chromatographic conditions are: Eclipse XDB-C8 column (150 × 4.6 mm, i.d. 5 μm); mobile phase [acetonitrile : 20 mM ammonium formate–100 mM potassium chloride buffer (pH 7.0) (30 : 70% v/v)]; flow rate = 1.5 mL min$^{-1}$; detector wavelength (UV) = 205 nm; and column temperature = 25 °C

| Parameters | Analyte | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | HRN | (**2a**) | (**2b**) | (**2c**) | (**2d**) | (**2e**) | (**2f**) | (**2g**) | (**2h**) | (**2i**) | (**2j**) | (**2k**) |
| $R^{2a}$ | 0.997[b] | 0.996[c] | 0.996[d] | 0.999[e] | 0.997[f] | 0.996[g] | 0.998[h] | 0.999[i] | 0.998[j] | 0.996[k] | 0.999[l] | 0.998[m] |
| LOD[n] (μg mL$^{-1}$) | 0.45 | 0.48 | 0.48 | 0.77 | 0.91 | 1.19 | 1.28 | 1.71 | 1.68 | 2.60 | 2.78 | 2.93 |
| LOQ[o] (μg mL$^{-1}$) | 1.49 | 1.61 | 1.61 | 2.58 | 3.04 | 3.95 | 4.27 | 5.71 | 5.59 | 8.68 | 9.26 | 9.76 |
| **Precision (%RSD, $n$ = 6)** | | | | | | | | | | | | |
| 10 μg mL$^{-1}$ | 0.01 | 0.73 | 0.76 | 0.85 | 0.40 | 0.95 | 0.05 | 0.48 | 0.56 | 0.20 | 0.32 | 0.89 |
| 40 μg mL$^{-1}$ | 0.10 | 0.57 | 0.06 | 0.55 | 0.38 | 0.13 | 0.49 | 0.81 | 0.16 | 0.41 | 0.79 | 0.06 |
| 60 μg mL$^{-1}$ | 0.30 | 0.45 | 0.06 | 0.06 | 0.05 | 0.23 | 0.29 | 0.31 | 0.19 | 0.83 | 0.85 | 0.32 |
| 80 μg mL$^{-1}$ | 0.20 | 0.15 | 0.09 | 0.06 | 0.13 | 0.11 | 0.08 | 0.33 | 0.11 | 0.20 | 0.77 | 0.06 |
| 100 μg mL$^{-1}$ | 0.11 | 0.65 | 0.40 | 1.05 | 0.14 | 0.17 | 0.21 | 0.01 | 0.00 | 0.31 | 0.61 | 0.49 |
| 120 μg mL$^{-1}$ | 0.92 | 0.84 | 0.33 | 0.63 | 0.27 | 0.60 | 0.82 | 0.21 | 0.31 | 0.93 | 0.96 | 0.32 |
| **System suitability parameters** | | | | | | | | | | | | |
| $t_R$ ± SD (min)[p] ($n$ = 6) | 2.80 ± 0.03 | 4.1 ± 0.04 | 4.80 ± 0.02 | 8.11 ± 0.04 | 10.80 ± 0.08 | 13.21 ± 0.05 | 14.27 ± 0.07 | 18.09 ± 0.01 | 20.66 ± 0.05 | 25.51 ± 0.03 | 27.65 ± 0.04 | 29.43 ± 0.06 |
| RRT[q] | 0.35 | 0.51 | 0.59 | 1 | 1.33 | 1.63 | 1.76 | 2.23 | 2.55 | 3.15 | 3.41 | 3.63 |
| $N$ (plates)[r] | 2101 | 5150 | 6620 | 8380 | 8920 | 9230 | 9600 | 9555 | 9545 | 9850 | 10 218 | 10 188 |
| $R_s$[s] | — | 4.69 | 2.82 | 10.41 | 6.57 | 4.75 | 1.86 | 5.74 | 3.18 | 5.10 | 1.88 | 1.50 |

[a] $R^2$: co-efficient of regression. [b] $y = 0.006x + 0.007$. [c] $y = 0.012x - 0.041$. [d] $y = 0.011x - 0.041$. [e] $y = 0.006x + 0.017$. [f] $y = 0.006x - 0.015$. [g] $y = 0.003x + 0.026$. [h] $y = 0.005x - 0.025$. [i] $y = 0.004x - 7 \times 10^{-5}$. [j] $y = 0.003x - 0.001$. [k] $y = 0.003x + 0.002$. [l] $y = 0.002x - 0.006$. [m] $y = 0.002x - 0.004$. [n] LOD: limit of detection. [o] LOQ: limit of quantitation. [p] $t_R$: retention time in minutes for drugs eluting from the flow-cell (Method II). [q] RRT: relative retention time (determined with respect to (**2c**) retention time obtained from Method II). [r] $N$: number of theoretical plates expressed in plates per m. [s] $R_s$: resolution between two successive eluted peaks.

prepared; one containing 50 μg mL$^{-1}$ of each of (Cf), (Bz) and the twelve investigated drugs, while the second solution was the same but (Cf) was substituted with (Pc). Fig. 3A and B depict the HPLC-DAD chromatogram and HPLC-AD amperogram for the first adulterated solution and Fig. 3C and D present the HPLC-DAD chromatogram and HPLC-AD amperogram for the second adulterated solution, respectively. The HPLC-AD amperogram is presented within Fig. 3D, which depicts a peak for (Pc) and a peak for (Bz) while the HPLC-AD amperogram, illustrated in Fig. 3B, gives rise to a sole peak for (Bz). Such a response is due to (Cf) undergoing an irreversible electrochemical oxidation process, at $E_p \approx +1.4$ V,[22,23] however, herein, HPLC-AD measurements were conducted at $E_p = +1.0$ V (vs. Ag/AgCl) hindering the oxidation of (Cf). Finally, the specificity of both analytical methodologies was tested upon injecting a solution containing 300 μg mL$^{-1}$ of potential diluents commonly found in pharmaceutical formulations (D-glucose, D-fructose, sucrose, lactose, starch, aerosil 200, sodium lauryl sulfate, stearic acid and sodium carboxymethyl cellulose). It was found that this solution did not show any peak in either HPLC-DAD chromatogram (Fig. S4A†) or HPLC-AD amperogram (Fig. S4B†). Also, a solution containing 300 μg mL$^{-1}$ of excipients and 50 μg mL$^{-1}$ of the investigated drugs was injected into the HPLC and the magnitude of the response (peak area and peak heights) of

each compound was monitored for both methods (Fig. S5†). It was found that the added excipients did not interfere and did not affect the analytical sensing of the investigated drugs by both methods; the additives added were UV-inactive and electrochemically inert. This demonstrates the high specificity and selectivity of the promised sensing protocols.

Three seized samples of suspected HRN, were provided under license by Greater Manchester Police and tested using our proposed HPLC-AD methodology in order to test the viability of the proposed protocol (as described in the Experimental section). As presented in Table 4, analysis of a 2 mg mL$^{-1}$ HSS1 solution resulted in a % w/w equals to 1.66 ± 0.02 and 1.48 ± 0.02 for (2c), using HPLC-DAD and HPLC-AD, respectively (Table 4). Results for HRN% were strongly correlated with those obtained with GC-MS, where the obtained % w/w for HRN = 26.70 ± 0.61, however, the proposed methods overestimated (2c)% when compared with that of GC/MS, (2c)% = 0.26 ± 1.16 (Table 4). The results obtained by HPLC-DAD and HPLC-AD methodologies when analyzing HSS2, (containing HRN, (Cf) and (Pc)) and HSS3 (containing HRN only) were in a good agreement with each other: HRN % w/w in HSS2 = 29.09 ± 0.57 and 27.42 ± 0.27 using HPLC-DAD and HPLC-AD, respectively (Table 4); HSS3, HRN % w/w = 60.09 ± 0.36 and 58.92 ± 0.83 using HPLC-DAD and HPLC-AD, respectively (Table 4). When



Fig. 3 (A) Representative HPLC-DAD chromatograms for a solution containing 50 μg mL$^{-1}$ of each of caffeine (Cf), HRN, benzocaine (Bz), fentanyl (2c) and its 10 derivatives using Eclipse XDB-C8 column (150 × 4.6 mm, i.d. 5 μm); mobile phase: acetonitrile : 20 mM ammonium formate–100 mM potassium chloride buffer (pH 7.0) (30 : 70% v/v); flow rate 1.5 mL min$^{-1}$, detector wavelength (UV): 205 nm and column temperature: 25 °C. (B) Representative amperogram for a solution containing 50 μg mL$^{-1}$ of each of caffeine (Cf), HRN, benzocaine (Bz), fentanyl and its 10 derivatives obtained using HPLC-AD flow cell system. (C) HPLC-DAD chromatogram for a solution containing 50 μg mL$^{-1}$ of each of paracetamol (Pc), HRN, benzocaine (Bz), fentanyl and fentalogues. (D) Representative amperogram for a solution containing 50 μg mL$^{-1}$ of each of paracetamol (Pc), HRN, benzocaine (Bz), (2c) and fentalogues using HPLC-AD flow cell system.

**Table 4** Comparison of data obtained using HPLC–DAD, HPLC–AD and GC/MS methodologies for the analysis of seized street samples

| Method of detection | Detected drugs of abuse | | | | | | | | | | | |
| | HPLC–DAD (Method I) | | | | HPLC–AD (Method II) | | | | GC/MS | | | |
| Analyzed street sample | HRN (% w/w) ± SD$^a$ | RSD$^b$ (%) | (2c) (% w/w) ± SD$^a$ | RSD$^b$ (%) | HRN (% w/w) ± SD$^a$ | RSD$^b$ (%) | (2c) (% w/w) ± SD$^a$ | RSD$^b$ (%) | HRN (% w/w) ± SD$^a$ | RSD$^b$ (%) | (2c) (% w/w) ± SD$^a$ | RSD$^b$ (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $t_R$ (min) ± SD | 2.79 ± 0.03 | 1.08 | 8.10 ± 0.05 | 0.62 | 2.80 ± 0.03 | 1.07 | 8.11 ± 0.05 | 0.62 | 12.75 ± 0.02 | 0.16 | 13.84 ± 0.003 | 0.02 |
| HSS1 | 26.64 ± 0.31 | 1.16 | 1.66 ± 0.02 | 1.20 | 24.16 ± 0.18 | 0.75 | 1.48 ± 0.02 | 1.35 | 26.70 ± 0.61 | 2.28 | 0.26 ± 0.003 | 1.15 |
| HSS2 | 29.09 ± 0.57 | 1.96 | n.d.$^c$ | n.d.$^c$ | 27.42 ± 0.27 | 0.98 | n.d.$^c$ | n.d.$^c$ | 29.50 ± 0.52 | 1.76 | n.d.$^c$ | n.d.$^c$ |
| HSS3 | 60.09 ± 0.36 | 0.60 | n.d.$^c$ | n.d.$^c$ | 58.92 ± 0.83 | 1.41 | n.d.$^c$ | n.d.$^c$ | 62.70 ± 0.75 | 1.20 | n.d.$^c$ | n.d.$^c$ |

$^a$ Mean ± SD of obtained % w/w of three determinations of each detected drug in each street sample. $^b$ Percentage relative standard deviation of obtained % w/w of three determinations of each detected drug in each street sample. $^c$ n.d. = not detected.

comparing those results with GC/MS, we find that HRN % w/w = 29.50 ± 0.52 and 62.70 ± 0.75 for HSS2 and HSS3, respectively, emphasizing the reliability of the proposed protocol. Note that HSS1 and HSS2 have (Pc) and (Cf), both adulterants, which elute together as a single peak using the HPLC-DAD, whereas, in HPLC-AD only the (Pc) peak was visible.

In summary, in comparison of the two proposed detection protocols, there are no significant differences between them and both give rise to the reliable quantification of the target analytes. However, HPLC-AD demonstrates a slight underestimation in its values, which can be attributed to its relatively lower sensitivity comparing with the HPLC-DAD, but it is still suitable and sufficient for the quantification of heroin, fentanyl and fentalogues providing an analytically competitive protocol.

## Conclusions

For the first time, the analytical determination of HRN, fentanyl (2c) and fentalogues (2a, 2b, 2d–2k) is reported using a dual HPLC-DAD and HPLC-AD protocol employing a commercially available impinging jet flow-cell, incorporating SPEs. This methodology demonstrates high accuracy, precision and is in a good agreement with traditional HPLC-DAD. This HPLC-AD technique is the first to be used as a precursor/screening method for forensic samples. In addition, this method was successfully applied for the analysis of the target analytes without interference of common formulated excipients or potential adulterants found in street samples.

## Experimental section

### Chemicals and materials

All reagents are of commercial quality (Sigma-Aldrich, Gillingham, UK or Fluorochem Limited, Hadfield, UK) and used without further purification. All aqueous solutions were prepared with Milli-Q deionized water of resistively ≥ 18.2 Ω cm (Millipore system). All solutions (unless stated otherwise) were vigorously degassed, with highly pure nitrogen to remove oxygen prior to analysis. Solvents (Fisher Scientific, Loughborough, UK) were dried, where necessary, using standard

procedures. The target compounds (2a–2k) were synthesized, from 4-ANPP (1), using an adaptation of the method reported by Valdez et al.[24] and obtained as stable, off-white powders (Scheme 1). The hydrochloride salts were determined to be soluble (10 mg mL$^{-1}$) in deionised water, methanol and dimethylsulfoxide. To ensure the authenticity of the materials utilized in this study the synthesized samples were structurally characterized (see ESI† for more details) by both $^1$H-NMR and $^{13}$C-NMR and the purity of all samples was confirmed by NMR and GC-MS (>99.5% in all cases). $^1$H-NMR and $^{13}$C-NMR spectra were acquired on a JEOL AS-400 (JEOL, Tokyo, Japan) NMR spectrometer operating at a proton resonance frequency of 400 MHz and referenced to the residual solvent peak (d$_6$-DMSO: $^1$H-NMR δ = 2.50 ppm, $^{13}$C-NMR δ = 39.52 ppm). Three seized samples of heroin were provided by Greater Manchester Police, in accordance with license requirements and agreed procedures. Details of the street samples utilized are presented within the ESI.†

### Instrumentation

**High performance liquid chromatography-diode array detection (HPLC-DAD).** Reverse phase HPLC was performed with an integrated Agilent HP Series 1100 Liquid Chromatography Instrument (Agilent Technologies, Wokingham, UK), consisting of an Agilent 1100 Series Quaternary pump G1310A (Serial DE80301064), an Agilent 1100 Series Vacuum Degasser G1322A (Serial JP73017007) and an Agilent 1100 Series Diode Array detector G1315A (Serial DE74603601), which was monitored at a wavelength of 205 nm. The LC system is equipped with Agilent 1100 Series Thermostated Column Compartment G1316A (Serial DE91810205) controlled at 25 °C, and a 100-place auto injector G1313A (Serial DE54901543), with an injection volume of 10.0 μL. The stationary phase used was an Eclipse XDB-C8 column (4.6 × 150 mm; i.d. particle size: 5 μm; Germany). The mobile phase was [acetonitrile : 20 mM ammonium formate–100 mM potassium chloride buffer (pH 7.0), 30 : 70% v/v] flowing at a rate of 1.5 mL min$^{-1}$. The LC system is connected to a computer loaded with Agilent Chemstation (Ver. 10.02) software (Agilent Technologies, Wokingham, UK) for data analysis.

**High-performance liquid chromatography-amperometric detection (HPLC-AD).** The HPLC was coupled, in sequence, to a commercially available impinging jet flow cell obtained from Dropsens, Spain (product code: DRP-FLWCL-TEF-71306; $3.3 \times 6.0 \times 3.3$ cm, flow chamber volume = 8 μL) housing the SPE. The SPEs utilized in this part were fabricated in-house as previously mentioned above.[9,25] Amperometric measurements were carried out using a Palmsens Emstat3 (Palmsens BV, The Netherlands) potentiostat/galvanostat and controlled by PSTrace (version 4.4) software. All the amperometric measurements were carried out at 25 °C using the following parameters: (i) potential ($E$, +1.0 V $vs.$ Ag/AgCl); (ii) equilibration time ($t$-equilibration, 10.0 s); (iii) data interval ($t$-interval, 0.08 s); (iv) current range (100 nA to 1 mA) and (iv) total run time ($t$-run, 3000 s).

**Preparation of the mobile phase [acetonitrile : 20 mM ammonium formate–100 mM potassium chloride buffer (pH 7.0), 30 : 70% v/v].** The buffer system (20 mM ammonium formate–100 mM potassium chloride) was prepared into a 2.0 L volumetric flask by dissolving 2.52 g of ammonium formate and 14.91 g of potassium chloride in ultrapure deionized water, the pH was adjusted by the dropwise addition of 0.1 M NaOH to pH 7.0. Afterwards, appropriate proportions of each of the buffer and organic modifier were mixed to obtain a 2.0 L mobile phase of the desired ratio. Prior to use, the mobile phase was vacuum filtered through a 0.45 mm pore filter paper and degassed for 10 min at 25 °C using an ultrasonic bath.

**Preparation of standard stock solution and calibration curve for HPLC-DAD and HPLC-AD.** 12.5 mg of each of HRN, fentanyl hydrochloride (**2c**) and its fentalogues (**2a, 2b, 2d–2k**) were weighted accurately into a 25.0 mL clear glass volumetric flask and diluted to volume with mobile phase to give a stock solution containing 0.5 mg mL$^{-1}$ of each drug (S). Working solutions for calibration standards were prepared by further dilution of the latter solution (S) with the mobile phase to give solutions containing 5 μg mL$^{-1}$, 10 μg mL$^{-1}$, 20 μg mL$^{-1}$, 40 μg mL$^{-1}$, 60 μg mL$^{-1}$, 80 μg mL$^{-1}$, 100 μg mL$^{-1}$ and 120 μg mL$^{-1}$ of each analyte. Working solutions were injected directly into the HPLC and the peak areas (for HPLC-DAD analysis) and peak heights (for HPLC-AD analysis) of the studied drugs are plotted against their corresponding concentrations to construct the calibration curves. All solutions were covered with aluminum foil and the stock solution was kept in the refrigerator at 4 °C for two weeks.

**Selectivity standards.** 12.5 mg of caffeine (Cf), paracetamol (Pc) and benzocaine (Bz) were weighted separately into three 25.0 mL glass volumetric flasks and diluted to volume with the mobile phase to obtain a stock solution of 0.5 mg mL$^{-1}$ for each component. 0.5 mL from each stock solution were taken separately into three 5.0 mL volumetric flask, completed to volume with the mobile phase and each solution was injected separately into the HPLC to monitor the retention time ($t_R$) for each compound. 0.5 mL from both caffeine (Cf) and benzocaine (Bz) and/or paracetamol (Pc) and benzocaine (Bz) were added to a 5.0 mL volumetric flask containing 0.5 mL of the drug stock solution (S), the flasks were completed to the mark with the mobile phase and injected into the HPLC.

**Specificity standards.** 10.0 mg of each of D-glucose, D-fructose, sucrose, lactose, starch, aerosil 200, sodium lauryl sulfate, stearic acid and sodium carboxymethyl cellulose were weighted accurately into one 20.0 mL glass volumetric flasks, dissolved in the mobile phase, sonicated for 20 minutes and diluted to volume with the same solvent to obtain a stock solution of 0.5 mg mL$^{-1}$ for each component. 3.0 mL of the prepared solution were transferred into a 5.0 mL volumetric flask, diluted to the mark with the mobile phase and injected into the HPLC. Another 3.0 mL of the excipient solution were added to a 5.0 mL volumetric flask containing 0.5 mL from the drug stock solution (S), the flask was mixed, and made up to volume with the mobile phase and injected into the HPLC.

**Application of the HPLC-DAD and HPLC-AD methods towards seized street samples.** Three HRN containing street samples seized by Greater Manchester Police were brought to our authorized lab. The homogenized samples were arbitrarily labeled as heroin street sample 1 (HSS1), heroin street sample 2 (HSS2) and heroin street sample 3 (HSS3). 12.5 mg from each street sample were accurately weighted (in triplicate) and added separately into 25.0 mL volumetric flasks, diluted with the mobile phase, sonicated for 20 minutes and made to the mark with the latter solvent. The obtained solutions were filtered through 0.2 μm PTFE syringe filters and 1.0 mL from each filtered solution was transferred separately into 5.0 mL volumetric flasks, made to volume with the mobile phase and injected into the HPLC system. The first street sample (HHS1) was analyzed again (in triplicate) by preparing a more concentrated solution consisting of 50.0 mg of HHS1 homogenized powder added to a 25.0 mL volumetric flask, diluted with the eluent, sonicated for 20 minutes, completed to the mark with the mobile phase, filtered with 0.2 μm PTFE syringe filters and injected directly into the HPLC. Gas chromatography/mass spectrometric analysis (GC/MS) was performed for the three street samples using the following conditions: HP-5 MS column (30 m × 0.25 mm, 0.25 μm), helium is the carrier gas flowing at a rate of 1.2 mL min$^{-1}$ and the following temperature gradient program was adopted: starting with $T = 100$ °C, which ramped linearly until 200 °C, at a rate of 30 °C min$^{-1}$, over 3.33 minutes, with the temperature ramped further until 260 °C, at a rate of 10 °C min$^{-1}$, for 6.33 minutes, afterwards the temperature was held constant for 10 minutes at 260 °C.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

# References

1 P. W. Peng and A. N. Sandler, *Anesthesiology*, 1999, **90**, 576–599.

2 M. LaBarbera and T. Wolfe, *J. Psychoact. Drugs*, 1983, **15**, 293–301.

3 M. N. Pastore, Y. N. Kalia, M. Horstmann and M. S. Roberts, *Br. J. Pharmacol.*, 2015, **172**, 2179–2209.

4 M. I. Jumbelic, *Am. J. Forensic Med. Pathol*, 2010, **31**, 18–21.

5 D. A. Algren, C. P. Monteilh, M. Punja, J. G. Schier, M. Belson, B. R. Hepler, C. J. Schmidt, C. E. Miller, M. Patel, L. J. Paulozzi, M. Straetemans and C. Rubin, *J. Med. Toxicol.*, 2013, **9**, 106–115.

6 https://www.dea.gov/pr/multimedia-library/publications/drug_of_abuse.pdf, accessed 20 Jun 2018.

7 J. Mounteney, I. Giraudon, G. Denissov and P. Griffiths, *Int. J. Drug Pol.*, 2015, **26**, 626–631.

8 C. M. Selavka, I. S. Krull and I. S. Lurie, *J. Chromatogr. Sci.*, 1985, **23**, 499–508.

9 K. Y. Zuway, J. P. Smith, C. W. Foster, N. Kapur, C. E. Banks and O. B. Sutcliffe, *Analyst*, 2015, **140**, 6283–6294.

10 L. R. Cumba, J. P. Smith, K. Y. Zuway, O. B. Sutcliffe, D. R. do Carmo and C. E. Banks, *Anal. Methods*, 2016, **8**, 142–152.

11 M. A. Mohamed, S. A. Atty, A. M. Yehia, C. W. Foster, C. E. Banks and N. K. Allam, *ACS Omega*, 2017, **2**, 6628–6635.

12 M. A. Mohamed, D. M. El-Gendy, N. Ahmed, C. E. Banks and N. K. Allam, *Biosens. Bioelectron.*, 2018, **101**, 90–95.

13 C. M. Selavka and I. S. Krull, *J. Liq. Chromatogr.*, 1987, **10**, 345–375.

14 J. M. P. J. Garrido, M. P. M. Marques, A. M. S. Silva, T. R. A. Macedo, A. M. Oliveira-Brett and F. Borges, *Anal. Bioanal. Chem.*, 2007, **388**, 1799–1808.

15 M. de Jong, N. Sleegers, J. Kim, F. Van Durme, N. Samyn, J. Wang and K. De Wael, *Chem. Sci.*, 2016, **7**, 2364–2370.

16 J. Garrido, C. Delerue-Matos, F. Borges, T. R. Macedo and A. Oliveira-Brett, *Electroanalysis*, 2004, **16**, 1497–1502.

17 J. R. Barreira Rodriguez, V. Cabal Diaz, A. Costa Garcia and P. Tunon Blanco, *Analyst*, 1990, **115**, 209–212.

18 R. Guidelli, *J. Electroanal. Chem. Interfacial Electrochem.*, 1971, **33**, 291–302.

19 R. Guidelli, *J. Electroanal. Chem. Interfacial Electrochem.*, 1971, **33**, 303–317.

20 K. B. Oldham, *J. Electroanal. Chem. Interfacial Electrochem.*, 1973, **41**, 351–358.

21 ICH, *Q2(R1), Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonization*, Geneva, 2005.

22 A. Câmpean, M. Tertiş and R. Săndulescu, *Cent. Eur. J. Chem.*, 2011, **9**, 466–473.

23 B. C. Lourençāo, R. A. Medeiros, R. C. Rocha-Filho, L. H. Mazo and O. Fatibello-Filho, *Talanta*, 2009, **78**, 748–752.

24 C. A. Valdez, R. N. Leif and B. P. Mayer, *PLoS One*, 2014, **9**, e108250.

25 J. P. Smith, J. P. Metters, C. Irving, O. B. Sutcliffe and C. E. Banks, *Analyst*, 2014, **139**, 389–400.

26 F. Bravo, D. Gonzalez and J. Benites, *J. Chem. Soc.*, 2011, **56**, 799–802.

27 M. R. Boleda, M. T. Galceran and F. Ventura, *J. Chromatogr. A*, 2007, **1175**, 38–48.

28 E. Sisco, J. Verkouteren, J. Staymates and J. Lawrence, *Forensic Chem.*, 2017, **4**, 108–115.

29 M. Gergov, P. Nokua, E. Vuori and I. Ojanperä, *Forensic Sci. Int.*, 2009, **186**, 36–43.

30 K. E. Strayer, H. M. Antonides, M. P. Juhascik, R. Daniulaityte and I. E. Sizemore, *ACS Omega*, 2018, **3**, 514–523.

31 S. Sofalvi, H. E. Schueler, E. S. Lavins, C. K. Kaspar, I. T. Brooker, C. D. Mazzola, D. Dolinak, T. P. Gilson and S. Perch, *J. Anal. Toxicol.*, 2017, **41**, 473–483.

32 A. Skulska, M. Kala and A. Parczewski, *Przegl. Lek.*, 2005, **62**, 581–584.

33 S. Strano-Rossi, I. Alvarez, M. J. Tabernero, P. Cabarcos, P. Fernandez and A. M. Bermejo, *J. Appl. Toxicol.*, 2011, **31**, 649–654.

34 I. S. Lurie, A. C. Allen and H. J. Issaq, *J. Liq. Chromatogr.*, 1984, **7**, 463–473.

35 L. J. Peng, M. L. Wen and Y. Yao, *J. Pharm. Biomed. Anal.*, 2002, **30**, 667–673.

36 L. J. Peng, M. L. Wen and Y. Yao, *Anal. Sci.*, 2001, **17**, 815–818.

37 H. Dai, H. Xu, X. Wu, Y. Chi and G. Chen, *Anal. Chim. Acta*, 2009, **647**, 60–65.

38 H. Guo, N. Hu and S. Lin, *Talanta*, 1994, **41**, 1929–1932.

39 G. H. N. L. Shuchang, *J. Beijing Norm. Univ., Nat. Sci.*, 1993, **3**, 21.